Compare ResMed Inc. (RMD) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Boston Beer Company Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Boston Beer Company Inc trades at $163.71 (market cap $1.67B). The key difference: ResMed Inc. is far larger — about 19.1× Boston Beer Company Inc's market cap, and ResMed Inc. pays a 1.19% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| RMD | SAM | |
|---|---|---|
Market Cap | $31.89B | $1.67B |
Sector | Health | Consumer Staples |
52-Week High | $283.28 | $260.05 |
52-Week Low | $182.82 | $161.08 |
Enterprise Value | $31.24B | $1.43B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
The Boston Beer Company (SAM) trades at $162.06, down 3.98% today, showing mixed signals with bearish technical indicators but positive cash flow trends. Recent earnings have missed expectations in Q1 and Q2 2026, though Q4 2025 beat estimates. The company maintains a debt-free balance sheet with strong operating cash flow of $270M in 2025, but faces volume declines and margin pressure.
SAM presents a cautious outlook with analyst consensus leaning Hold (71.87%) despite a $207.33 price target suggesting 28% upside. Key risks include declining alcohol consumption and execution challenges, while opportunities lie in new product launches and marketing leadership changes. The stock's valuation appears reasonable with P/E of 22.66 and P/S of 0.89.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
